REG - Allergy Therapeutics - Result of AGM

Allergy TherapeuticsAnnouncement

23/11/2021 12:55

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211123:nRSW3040Ta&default-theme=true

RNS Number : 3040T  Allergy Therapeutics PLC  23 November 2021

 

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Result of Annual General Meeting

 

 

23 November 2021 Allergy Therapeutics plc (AIM:AGY), the fully integrated
specialty pharmaceutical group specialising in allergy vaccines, announces
that, with the exception of resolution 10, which failed to carry, all other
resolutions proposed at the 2021 Annual General Meeting ("AGM") were duly
passed by shareholders. Voting was conducted by way of a poll.

 

Resolutions 1 to 9 (inclusive) were proposed as ordinary resolutions and
resolution 10 was proposed as a special resolution. The results of the poll
are outlined in the table below.

 

The Board acknowledges the failure to pass resolution 10 and is disappointed
in this outcome. The Board considers the flexibility afforded by these
authorities to be in the best interests of the Company and shareholders and
notes that this resolution has received support at previous AGMs. However, the
Board remains committed to continuing an open and transparent dialogue and
will, accordingly, seek to continue to engage with shareholders regarding
their views in this area.

 

 

 Resolution                                                                    For:         %age   Against:     %age   Withheld
 1.     To receive a copy of the Annual Report for the year ended 30 June      176,577,712  99.99  0            0      0
 2021
 2. To approve the Directors' Remuneration Report                              174,524,577  98.86  1,989,308    1.13   63,827
 3. To re-appoint Mary Tavener as a Director                                   176,161,541  99.98  7,089        0.01   409,082
 4. To re-appoint Scott Leinenweber as a Director                              173,381,457  98.41  2,787,173    1.58   409,082
 5. To re-appoint Tunde Otulana as a Director                                  176,161,541  99.98  7,089        0.01   409,082
 6. To re-appoint Peter Jensen as a Director                                   173,387,212  98.84  2,022,948    1.15   1,167,552
 7. To appoint BDO LLP as auditors of the Company                              176,142,079  99.97  32,806       0.02   402,827
 8. To authorise the Directors to determine the Auditors remuneration          176,577,712  99.99  0            0      0
 9. To authorise the Directors to allot unissued share capital up to a         176,565,019  99.98  11,693       0.01   1,000
 specified amount (s551)
 10 Special Resolution:                                                        37,107,171   21.00  139,469,541  78.99  1,000

 To disapply pre-emption provisions of s561(1) of the CoAct 2006 up to a
 specified amount

 

 

 

- ENDS -

 

For further information, please contact:

 

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international specialty pharmaceutical group
focussed on the treatment and diagnosis of allergic disorders, including
immunotherapy vaccines, that have the potential to cure disease. The Group
sells proprietary and third party products from its subsidiaries in nine major
European countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development include
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories.  The Group, which
has achieved double digit compound annual growth since formation, employs
c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFEEFEDEFSEIF